CClinicalTrials.gg
CompletedNCT06504173Updated Jul 16, 2024

Diced Cartilage in Breast Reconstruction

An observational study in Mammaplasty, Microsurgery and Rip Reconstruction Cartilage, sponsored by ISAR Klinikum. Completed at 2 sites in Germany. Open to female participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by ISAR Klinikum · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
173
Ages
18 Years to 99 Years
Sex
Female
01

Study summary

Exposure of internal mammary vessels in autologous breast reconstruction often requires removal of a rib cartilage segment, which can lead to contour deformity in the craniomedial breast pole. This study evaluated the use of diced cartilage (DC) to counteract substance loss in the microvascular anastomosis area, and investigated safety and suitability of the procedure to avoid postoperative deformities.

Read the detailed description

This retrospective, single-center cohort study included all breast reconstructions in which DC was used from October 2021 to June 2023. Reconstructions using DC were subdivided based on previous exposure to breast radiotherapy (DC vs. DCR). The control group consisted of an equal number of consecutive reconstructions performed prior to the use of DC. The effect of DC on breast contour preservation was investigated using breast magnetic resonance imaging (MRI; > 6 months post-op) and photographic documentation (6-month follow-up).

02

Conditions studied

  • Mammaplasty
  • Microsurgery
  • Rip Reconstruction Cartilage
03

In context

Lead sponsor

ISAR Klinikum is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of women who received autologous free flap breast reconstruction using internal mammary vessels as recipient vessels.

Inclusion criteria

  • Autologous free flap breast reconstruction using the internal mammary vessels as recipient vessels from October 2021 to June 2023
  • MRI subcohort: Magnetic resonance imaging (MRI) scans performed at least 6 months postoperatively

Exclusion criteria

Exclusion Criteria:

  • Autologous free flap breast reconstruction using a perforator of the internal mammary vessels as recipient vessels from October 2021 to June 2023
  • Autologous free flap breast reconstruction using the thoracodorsal vessels as recipient vessels from October 2021 to June 2023
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
173 participants (actual)
Patient registry
No

Groups and cohorts

  • diced cartilage (DC)

    After removing a part of the rip cartilage and microsurgery, the exposed internal mammary vessels in autologous free flap breast reconstruction was restored with diced cartilage (DC) out of the removed rip cartialge.

    Procedure: diced cartilage

  • control

    After removing a part of the rip cartilage and microsurgery, the exposed internal mammary vessels in autologous free flap breast reconstruction was NOT restored.

Interventions

  • Procedurediced cartilage

    In reconstructions using DC management of IMVES, the surgical nurse processed the removed cartilage into DC using a dermatome blade. Cartilage pieces of approximately 0,5-1 mm were used. After microvascular anastomosis (coupler device for venous anastomosis; Synovis MCA, Birmingham AL, USA), all DC was placed back into the rib removal zone using a blunt dissector. The vessels were embedded and stabilized in cartilage paste according to the desired orientation.

06

What researchers measure

Primary outcomes

  1. Magnetic resonance imaging (MRI) scans: soft tissue sinking of the recipient vessels area

    the sinking depth of epicostal soft tissue into the space of rib segment resection on axial planes in Magnetic resonance imaging (MRI) scans performed at least 6 months postoperatively

    Time frame: October 2021 to June 2023

Secondary outcomes

  1. Visual contour deficit of the recipient vessels area

    Postoperative photographic images were examined by two investigators (blinded to group assignments) for IMVES-associated deformities using standardized photographic images of the reconstructed breasts at the 6-month follow-up.

    Time frame: October 2021 to June 2023

07

Study locations

2 sites
  • ISAR Klinikum - Department Plastic Surgery
    Munich, Bavaria 80331, Germany
  • ISAR Klinikum
    Munich, Bavaria 80331, Germany
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jul 10, 2024

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06504173
Lead sponsor
ISAR Klinikum
Collaborators
Breast Imaging Division, Radiologie Augsburg Friedberg / Breast Center Augsburg, Augsburg, Germany
Responsible party
Peter Paul Pfeiler, MD (Consultant, ISAR Klinikum) — Principal investigator
First posted
Jul 16, 2024
Start date
Jan 1, 2024
Primary completion
Jun 30, 2024
Completion
Jul 1, 2024
Last update
Jul 16, 2024

Study contacts

Ulf Dornseifer, MD/PhD
study director · Head of Department plastic and reconstructive surgery ISAR Klinikum

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion